

=> b reg
FILE 'REGISTRY' ENTERED AT 11:33:24 ON 29 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 APR 2008 HIGHEST RN 1017984-01-8
DICTIONARY FILE UPDATES: 28 APR 2008 HIGHEST RN 1017984-01-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:33:48 ON 29 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Apr 2008 VOL 148 ISS 18
FILE LAST UPDATED: 28 Apr 2008 (20080428/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitrn l18 tot

L18 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 AN 2006:R12216 HCAPLUS
 DN 145:241683
 TI Pyridazine-based SCD-1 inhibitors for use in combination therapy to treat
 adverse weight gain associated with a drug therapy
 IN Sadalapur, Kashinath; Abreo, Melwyn; Kondratenko, Mikhail; Harvey,
 Daniel; Hudson, Cindy; Li, Wenbao; Tu, Chi; Sun, Sengen; Holladay, Mark;
 Gschwend, Heinz; Kamboj, Rajender; Winther, Michael; Fraser, Robert;
 Chafey, Mikhail; Fu, Jian-Kin; Hou, Duanjie; Liu, Shifeng; Reina, Vandna;
 Seid Bagherzadeh, Mehran
 PA Xenon Pharmaceuticals Inc., Can.
 SO PCT Int. Appl., 149pp.
 CO:EN: PXXD:
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2006086445	A2	20060817	2006WO-US0004383	20060208
WO-2006086445	A3	20060914		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CP, CU, CE, DE, DK, DM, EE, EC, EG, ES, FI, GB, GD, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, PR, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TR, TT, TZ, UA, UG, US, VE, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU-2006212761	A1	20060817	2006AU-000212761	20060208
CA-2597067	A1	20060817	2006CA-002597067	20060208
EP-1846035	A2	20071024	2006EP-000734555	20060208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, MX-200709592 A 20071016 2007MX-00009592 20070808				
IN-2007CN03940	A	20071123	2007IN-CN003940	20070910
CN-101163504	A	20080416	2006CN-080009724	20070925
PRAI 2005US-00651584P	P	20050209		
2006WO-US0004383	W	20060208		
MARPAT 145:241683				
GI				



AB This invention is directed to the use of SCD-1 inhibitors of the formula I
 [n, m = independently 1-3; w = a direct bond, NHCO and derivs., O, OCONH
 and derivs., CO, NH(C=NH)NH and derivs., etc.; v = CO, CS, CONH and
 derivs., etc.; G, J, L, M = independently N, CH and derivs., provided that
 at most 2 of G, J, L, and M are R; R2, R3 = independently alk(en)yl, aryl,

L18 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 etc.; each R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R99, R100, R101, R102, R103, R104, R105, R106, R107, R108, R109, R110, R111, R112, R113, R114, R115, R116, R117, R118, R119, R120, R121, R122, R123, R124, R125, R126, R127, R128, R129, R130, R131, R132, R133, R134, R135, R136, R137, R138, R139, R140, R141, R142, R143, R144, R145, R146, R147, R148, R149, R150, R151, R152, R153, R154, R155, R156, R157, R158, R159, R160, R161, R162, R163, R164, R165, R166, R167, R168, R169, R170, R171, R172, R173, R174, R175, R176, R177, R178, R179, R180, R181, R182, R183, R184, R185, R186, R187, R188, R189, R190, R191, R192, R193, R194, R195, R196, R197, R198, R199, R200, R201, R202, R203, R204, R205, R206, R207, R208, R209, R210, R211, R212, R213, R214, R215, R216, R217, R218, R219, R220, R221, R222, R223, R224, R225, R226, R227, R228, R229, R230, R231, R232, R233, R234, R235, R236, R237, R238, R239, R240, R241, R242, R243, R244, R245, R246, R247, R248, R249, R250, R251, R252, R253, R254, R255, R256, R257, R258, R259, R260, R261, R262, R263, R264, R265, R266, R267, R268, R269, R270, R271, R272, R273, R274, R275, R276, R277, R278, R279, R280, R281, R282, R283, R284, R285, R286, R287, R288, R289, R290, R291, R292, R293, R294, R295, R296, R297, R298, R299, R300, R301, R302, R303, R304, R305, R306, R307, R308, R309, R310, R311, R312, R313, R314, R315, R316, R317, R318, R319, R320, R321, R322, R323, R324, R325, R326, R327, R328, R329, R330, R331, R332, R333, R334, R335, R336, R337, R338, R339, R340, R341, R342, R343, R344, R345, R346, R347, R348, R349, R350, R351, R352, R353, R354, R355, R356, R357, R358, R359, R360, R361, R362, R363, R364, R365, R366, R367, R368, R369, R370, R371, R372, R373, R374, R375, R376, R377, R378, R379, R380, R381, R382, R383, R384, R385, R386, R387, R388, R389, R390, R391, R392, R393, R394, R395, R396, R397, R398, R399, R400, R401, R402, R403, R404, R405, R406, R407, R408, R409, R410, R411, R412, R413, R414, R415, R416, R417, R418, R419, R420, R421, R422, R423, R424, R425, R426, R427, R428, R429, R430, R431, R432, R433, R434, R435, R436, R437, R438, R439, R440, R441, R442, R443, R444, R445, R446, R447, R448, R449, R450, R451, R452, R453, R454, R455, R456, R457, R458, R459, R460, R461, R462, R463, R464, R465, R466, R467, R468, R469, R470, R471, R472, R473, R474, R475, R476, R477, R478, R479, R480, R481, R482, R483, R484, R485, R486, R487, R488, R489, R490, R491, R492, R493, R494, R495, R496, R497, R498, R499, R500, R501, R502, R503, R504, R505, R506, R507, R508, R509, R510, R511, R512, R513, R514, R515, R516, R517, R518, R519, R520, R521, R522, R523, R524, R525, R526, R527, R528, R529, R530, R531, R532, R533, R534, R535, R536, R537, R538, R539, R540, R541, R542, R543, R544, R545, R546, R547, R548, R549, R550, R551, R552, R553, R554, R555, R556, R557, R558, R559, R560, R561, R562, R563, R564, R565, R566, R567, R568, R569, R570, R571, R572, R573, R574, R575, R576, R577, R578, R579, R580, R581, R582, R583, R584, R585, R586, R587, R588, R589, R590, R591, R592, R593, R594, R595, R596, R597, R598, R599, R600, R601, R602, R603, R604, R605, R606, R607, R608, R609, R610, R611, R612, R613, R614, R615, R616, R617, R618, R619, R620, R621, R622, R623, R624, R625, R626, R627, R628, R629, R630, R631, R632, R633, R634, R635, R636, R637, R638, R639, R640, R641, R642, R643, R644, R645, R646, R647, R648, R649, R650, R651, R652, R653, R654, R655, R656, R657, R658, R659, R660, R661, R662, R663, R664, R665, R666, R667, R668, R669, R670, R671, R672, R673, R674, R675, R676, R677, R678, R679, R680, R681, R682, R683, R684, R685, R686, R687, R688, R689, R690, R691, R692, R693, R694, R695, R696, R697, R698, R699, R700, R701, R702, R703, R704, R705, R706, R707, R708, R709, R710, R711, R712, R713, R714, R715, R716, R717, R718, R719, R720, R721, R722, R723, R724, R725, R726, R727, R728, R729, R730, R731, R732, R733, R734, R735, R736, R737, R738, R739, R740, R741, R742, R743, R744, R745, R746, R747, R748, R749, R750, R751, R752, R753, R754, R755, R756, R757, R758, R759, R760, R761, R762, R763, R764, R765, R766, R767, R768, R769, R770, R771, R772, R773, R774, R775, R776, R777, R778, R779, R780, R781, R782, R783, R784, R785, R786, R787, R788, R789, R790, R791, R792, R793, R794, R795, R796, R797, R798, R799, R800, R801, R802, R803, R804, R805, R806, R807, R808, R809, R810, R811, R812, R813, R814, R815, R816, R817, R818, R819, R820, R821, R822, R823, R824, R825, R826, R827, R828, R829, R830, R831, R832, R833, R834, R835, R836, R837, R838, R839, R840, R841, R842, R843, R844, R845, R846, R847, R848, R849, R850, R851, R852, R853, R854, R855, R856, R857, R858, R859, R860, R861, R862, R863, R864, R865, R866, R867, R868, R869, R870, R871, R872, R873, R874, R875, R876, R877, R878, R879, R880, R881, R882, R883, R884, R885, R886, R887, R888, R889, R890, R891, R892, R893, R894, R895, R896, R897, R898, R899, R900, R901, R902, R903, R904, R905, R906, R907, R908, R909, R910, R911, R912, R913, R914, R915, R916, R917, R918, R919, R920, R921, R922, R923, R924, R925, R926, R927, R928, R929, R930, R931, R932, R933, R934, R935, R936, R937, R938, R939, R940, R941, R942, R943, R944, R945, R946, R947, R948, R949, R950, R951, R952, R953, R954, R955, R956, R957, R958, R959, R960, R961, R962, R963, R964, R965, R966, R967, R968, R969, R970, R971, R972, R973, R974, R975, R976, R977, R978, R979, R980, R981, R982, R983, R984, R985, R986, R987, R988, R989, R990, R991, R992, R993, R994, R995, R996, R997, R998, R999, R1000, R1001, R1002, R1003, R1004, R1005, R1006, R1007, R1008, R1009, R1010, R1011, R1012, R1013, R1014, R1015, R1016, R1017, R1018, R1019, R1020, R1021, R1022, R1023, R1024, R1025, R1026, R1027, R1028, R1029, R1030, R1031, R1032, R1033, R1034, R1035, R1036, R1037, R1038, R1039, R1040, R1041, R1042, R1043, R1044, R1045, R1046, R1047, R1048, R1049, R1050, R1051, R1052, R1053, R1054, R1055, R1056, R1057, R1058, R1059, R1060, R1061, R1062, R1063, R1064, R1065, R1066, R1067, R1068, R1069, R1070, R1071, R1072, R1073, R1074, R1075, R1076, R1077, R1078, R1079, R1080, R1081, R1082, R1083, R1084, R1085, R1086, R1087, R1088, R1089, R1090, R1091, R1092, R1093, R1094, R1095, R1096, R1097, R1098, R1099, R1100, R1101, R1102, R1103, R1104, R1105, R1106, R1107, R1108, R1109, R1110, R1111, R1112, R1113, R1114, R1115, R1116, R1117, R1118, R1119, R1120, R1121, R1122, R1123, R1124, R1125, R1126, R1127, R1128, R1129, R1130, R1131, R1132, R1133, R1134, R1135, R1136, R1137, R1138, R1139, R1140, R1141, R1142, R1143, R1144, R1145, R1146, R1147, R1148, R1149, R1150, R1151, R1152, R1153, R1154, R1155, R1156, R1157, R1158, R1159, R1160, R1161, R1162, R1163, R1164, R1165, R1166, R1167, R1168, R1169, R1170, R1171, R1172, R1173, R1174, R1175, R1176, R1177, R1178, R1179, R1180, R1181, R1182, R1183, R1184, R1185, R1186, R1187, R1188, R1189, R1190, R1191, R1192, R1193, R1194, R1195, R1196, R1197, R1198, R1199, R1200, R1201, R1202, R1203, R1204, R1205, R1206, R1207, R1208, R1209, R1210, R1211, R1212, R1213, R1214, R1215, R1216, R1217, R1218, R1219, R1220, R1221, R1222, R1223, R1224, R1225, R1226, R1227, R1228, R1229, R1230, R1231, R1232, R1233, R1234, R1235, R1236, R1237, R1238, R1239, R1240, R1241, R1242, R1243, R1244, R1245, R1246, R1247, R1248, R1249, R1250, R1251, R1252, R1253, R1254, R1255, R1256, R1257, R1258, R1259, R1260, R1261, R1262, R1263, R1264, R1265, R1266, R1267, R1268, R1269, R1270, R1271, R1272, R1273, R1274, R1275, R1276, R1277, R1278, R1279, R1280, R1281, R1282, R1283, R1284, R1285, R1286, R1287, R1288, R1289, R1290, R1291, R1292, R1293, R1294, R1295, R1296, R1297, R1298, R1299, R1300, R1301, R1302, R1303, R1304, R1305, R1306, R1307, R1308, R1309, R1310, R1311, R1312, R1313, R1314, R1315, R1316, R1317, R1318, R1319, R1320, R1321, R1322, R1323, R1324, R1325, R1326, R1327, R1328, R1329, R1330, R1331, R1332, R1333, R1334, R1335, R1336, R1337, R1338, R1339, R1340, R1341, R1342, R1343, R1344, R1345, R1346, R1347, R1348, R1349, R1350, R1351, R1352, R1353, R1354, R1355, R1356, R1357, R1358, R1359, R1360, R1361, R1362, R1363, R1364, R1365, R1366, R1367, R1368, R1369, R1370, R1371, R1372, R1373, R1374, R1375, R1376, R1377, R1378, R1379, R1380, R1381, R1382, R1383, R1384, R1385, R1386, R1387, R1388, R1389, R1390, R1391, R1392, R1393, R1394, R1395, R1396, R1397, R1398, R1399, R1400, R1401, R1402, R1403, R1404, R1405, R1406, R1407, R1408, R1409, R1410, R1411, R1412, R1413, R1414, R1415, R1416, R1417, R1418, R1419, R1420, R1421, R1422, R1423, R1424, R1425, R1426, R1427, R1428, R1429, R1430, R1431, R1432, R1433, R1434, R1435, R1436, R1437, R1438, R1439, R1440, R1441, R1442, R1443, R1444, R1445, R1446, R1447, R1448, R1449, R1450, R1451, R1452, R1453, R1454, R1455, R1456, R1457, R1458, R1459, R1460, R1461, R1462, R1463, R1464, R1465, R1466, R1467, R1468, R1469, R1470, R1471, R1472, R1473, R1474, R1475, R1476, R1477, R1478, R1479, R1480, R1481, R1482, R1483, R1484, R1485, R1486, R1487, R1488, R1489, R1490, R1491, R1492, R1493, R1494, R1495, R1496, R1497, R1498, R1499, R1500, R1501, R1502, R1503, R1504, R1505, R1506, R1507, R1508, R1509, R1510, R1511, R1512, R1513, R1514, R1515, R1516, R1517, R1518, R1519, R1520, R1521, R1522, R1523, R1524, R1525, R1526, R1527, R1528, R1529, R1530, R1531, R1532, R1533, R1534, R1535, R1536, R1537, R1538, R1539, R1540, R1541, R1542, R1543, R1544, R1545, R1546, R1547, R1548, R1549, R1550, R1551, R1552, R1553, R1554, R1555, R1556, R1557, R1558, R1559, R1560, R1561, R1562, R1563, R1564, R1565, R1566, R1567, R1568, R1569, R1570, R1571, R1572, R1573, R1574, R1575, R1576, R1577, R1578, R1579, R1580, R1581, R1582, R1583, R1584, R1585, R1586, R1587, R1588, R1589, R1590, R1591, R1592, R1593, R1594, R1595, R1596, R1597, R1598, R1599, R1600, R1601, R1602, R1603, R1604, R1605, R1606, R1607, R1608, R1609, R1610, R1611, R1612, R1613, R1614, R1615, R1616, R1617, R1618, R1619, R1620, R1621, R1622, R1623, R1624, R1625, R1626, R1627, R1628, R1629, R1630, R1631, R1632, R1633, R1634, R1635, R1636, R1637, R1638, R1639, R1640, R1641, R1642, R1643, R1644, R1645, R1646, R1647, R1648, R1649, R1650, R1651, R1652, R1653, R1654, R1655, R1656, R1657, R1658, R1659, R1660, R1661, R1662, R1663, R1664, R1665, R1666, R1667, R1668, R1669, R1670, R1671, R1672, R1673, R1674, R1675, R1676, R1677, R1678, R1679, R1680, R1681, R1682, R1683, R1684, R1685, R1686, R1687, R1688, R1689, R1690, R1691, R1692, R1693, R1694, R1695, R1696, R1697, R1698, R1699, R1700, R1701, R1702, R1703, R1704, R1705, R1706, R1707, R1708, R1709, R1710, R1711, R1712, R1713, R1714, R1715, R1716, R1717, R1718, R1719, R1720, R1721, R1722, R1723, R1724, R1725, R1726, R1727, R1728, R1729, R1730, R1731, R1732, R1733, R1734, R1735, R1736, R1737, R1738, R1739, R1740, R1741, R1742, R1743, R1744, R1745, R1746, R1747, R1748, R1749, R1750, R1751, R1752, R1753, R1754, R1755, R1756, R1757, R1758, R1759, R1760, R1761, R1762, R1763, R1764, R1765, R1766, R1767, R1768, R1769, R1770, R1771, R1772, R1773, R1774, R1775, R1776, R1777, R1778, R1779, R1780, R1781, R1782, R1783, R1784, R1785, R1786, R1787, R1788, R1789, R1790, R1791, R1792, R1793, R1794, R1795, R1796, R1797, R1798, R1799, R1800, R1801, R1802, R1803, R1804, R1805, R1806, R1807, R1808, R1809, R1810, R1811, R1812, R1813, R1814, R1815, R1816, R1817, R1818, R1819, R1820, R1821, R1822, R1823, R1824, R1825, R1826, R1827, R1828, R1829, R1830, R1831, R1832, R1833, R1834, R1835, R1836, R1837, R1838, R1839, R1840, R1841, R1842, R1843, R1844, R1845, R1846, R1847, R1848, R1849, R1850, R1851, R1852, R1853, R1854, R1855, R1856, R1857, R1858, R1859, R1860, R1861, R1862, R1863, R1864, R1865, R1866, R1867, R1868, R1869, R1870, R1871, R1872, R1873, R1874, R1875, R1876, R1877, R1878, R1879, R1880, R1881, R1882, R1883, R1884, R1885, R1886, R1887, R1888, R1889, R1890, R1891, R1892, R1893, R1894, R1895, R1896, R1

L18 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 ester (prepn. given) and piperazin-1-yl-(2-(trifluoromethyl)phenyl)methanone
 (prepn. given) in PhMe were added to a mixt. of Cs2CO3, Pd(OAc)2, and
 BINAP followed by heating at 100° for 26 h to give 13%
 5-[4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl]pyridine-2-carboxylic acid
 (3-phenylpropyl)amide.


II 842170-92-7P 842170-93-8P 842170-94-9P
 842170-95-0P 842170-96-1P 842170-97-2P
 842170-98-3P 842170-99-4P 842171-03-3P
 842171-04-4P 842171-05-5P 842171-06-6P
 842171-07-7P 842171-08-8P 842171-09-9P
 842171-10-2P 842171-12-4P 842171-15-7P
 842171-17-9P 842171-19-1P 842171-21-5P
 842171-23-7P 842171-25-9P 842171-27-1P
 842171-29-3P 842171-31-7P 842171-35-1P
 842171-37-3E 842171-39-5P 842171-41-9P
 842171-93-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of piperazinyipyridines as inhibitors of human
 stearyl CoA desaturase)

II 842171-55-5P 842171-57-7P 842171-59-9P
 842171-61-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of piperazinyipyridines as inhibitors of human stearyl CoA
 desaturase)


II 842170-92-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of piperazinyipyridines as inhibitors of human
 stearyl CoA desaturase)

RN 842170-92-7 HCAPLUS

CN Benzenepropanamide, 4-fluoro-N-[5-[4-[2-(trifluoromethyl)benzoyl]-1-
 piperazinyl]-2-pyridinyl]- (CA INDEX NAME)



=> d bib abs hitstr l2l tot


IX 

IX 361209-76-9P, N-[3-[[6-(4-(2,3,4,5-tetrafluorobenzoyl)picerazin-1-yl)propyl]-6-(4-(2,3,4,5-tetrafluorobenzoyl)picerazin-1-yl)picolinamide, 361209-79-2P.


[illegible][illegible][illegible]

121 ANSWER 1 OF 51 CAPSULUS COPYRIGHT 2008 CAS ON STN (Continued)
trifluoromethoxybenzoyl)piperazin-1-yl]nicotiname 825550-46-OP,
6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
isopropoxypropyl)nicotiname 825550-50-OP, 6-[4-(2,3-Ethoxypropyl)-6-
[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotiname
825550-48-2P, N-Butyl-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-N-(2-
ethylfuran-2-yl)nicotiname 825550-50-OP, 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
isopropoxypropyl)nicotiname 825550-51-OP,
6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
isopropoxypropyl)nicotiname 825550-52-4P, N-(3-Butoxypropyl)-6-[4-(2-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-53-3P,
825550-53-9P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(2-
ethylfuranylethyl)nicotiname 825550-54-OP,
N-Propoxypropyl-6-[4-(2-ethylfuranylethyl)piperazin-1-yl]-N-(2-
ethylfuranylethyl)nicotiname 825550-55-1P, 6-[4-(2,5-
Dichlorobenzoyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotiname 825550-56-4P,
825550-56-4P, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP,
methylbutyl)nicotiname 825550-57-3P, 6-[4-(3,5-
Dichlorobenzoyl)piperazin-1-yl]-N-(2-methylbutyl)nicotiname 825550-58-4P,
825550-58-4P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(2-
ethylfuranylethyl)nicotiname 825550-59-3P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-
Dimethylbutyl)nicotiname 825550-60-4P, 6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(2-
ethylfuranylethyl)nicotiname 825550-60-6P, 6-[4-(2-Bromo-3-
methoxypropyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotiname 825550-61-3P,
825550-61-9P, N-(3-Dimethylaninopropyl)-6-[4-(2-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-62-OP,
825550-62-OP, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(3-ethylbutyl)nicotiname
825550-64-2P, N-(3-Isopropoxypropyl)-6-[4-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-65-3P,
6-[4-(2-Bromo-3-methoxypropyl)piperazin-1-yl]nicotiname 825550-66-4P,
825550-66-4P, 6-[4-(2-Ethoxybenzoyl)piperazin-1-yl]-N-
hexylnicotiname 825550-67-5P, N-(3-Isopropoxypropyl)-6-[4-(2-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-68-6P,
6-[4-(2-Bromo-3-methoxypropyl)piperazin-1-yl]nicotiname 825550-68-6P,
N-methoxypropyl)nicotiname 825550-69-7P, 6-[4-(2-
Bromobenzoyl)piperazin-1-yl]-N-(1-methylbutyl)nicotiname
825550-70-2P, 6-[4-(3,5-Di-OP, 6-[4-(3,5-Di-OP, 6-[4-(3,5-Di-OP, 6-[4-(3,5-Di-OP,
hexylnicotiname 825550-71-1P, N-(3-Methoxypropyl)-6-[4-(2-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-72-2P,
6-[4-(2-Dichlorobenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotiname 825550-73-3P,
N-(2-Ethylfuranylethyl)-6-[4-(2-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-74-4P,
N-Pentyl-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]nicotiname
825550-75-2P, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP,
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-76-6P,
N-(2-Ethylfuranylethyl)-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
methylbutyl)nicotiname 825550-77-3P, 6-[4-(2-Ethylfuranylethyl)piperazin-1-yl]-N-(2-
methylbutyl)nicotiname 825550-78-8P,
N-(1,3-Dimethylbutyl)-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]nicotiname
825550-79-3P, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP,
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-80-2P,
6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(1-methylbutyl)nicotiname
825550-81-3P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-
methoxypropyl)nicotiname 825550-82-4P, 6-[4-(2-Ethylfuranylethyl)piperazin-1-yl]-N-(3-
methoxypropyl)nicotiname 825550-83-5P,
N-(3-Dimethylbutyl)-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
methylbutyl)piperazin-1-yl]-N-(1-methylbutyl)nicotiname
825550-84-4P, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP,
Dichlorobenzoyl)piperazin-1-yl]-N-(1-methylbutyl)nicotiname
825550-85-7P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(1-
methylbutyl)nicotiname 825550-86-4P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-87-9P,
6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-hexylnicotiname
825550-88-0P, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP, 6-[4-(2,4-Di-OP,
methoxypropyl)nicotiname 825550-89-1P, 6-[4-(3,5-
Dichlorobenzoyl)piperazin-1-yl]-N-(1-methylbutyl)nicotiname
825550-90-4P, N-(3-Butoxypropyl)-6-[4-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-91-5P,
6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-
isopropoxypropyl)nicotiname 825550-92-6P, N-(3-Methylbutyl)-6-[4-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname
825550-93-7P, N-Butyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-94-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-95-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-96-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-97-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-98-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-99-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-100-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-101-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-102-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-103-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-104-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-105-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-106-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-107-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-108-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-109-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
trifluoromethylbenzoyl)piperazin-1-yl]nicotiname 825550-110-4P,
N-Propyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-
triflu


L21	ANSMER 1 of 5 HCAPLUS COPYRIGHT 2008 ACS on GTN (Continued)
RM	N-Hexyl-6-[4-[(naphthalen-2-yl)carboxyl]piperazin-1-yl]nicotinamide 852551-52-IP; N-[3-(Dimethylamino)propyl]-6-[4-[(naphthalen-1- yl)nicotinamide-1-yl]carboxyl]piperazine 852551-52-IP; N-(2-Rhysylsulfonyl)-6-[4-[(naphthalen-2-yl)carboxyl]piperazin-1- yl]nicotinamide 852551-52-IP; N-[3-(Dimethylamino)propyl]-6-[4- [(naphthalen-2-yl)carboxyl]piperazin-1-yl]nicotinamide Pharmacology: (Preparation); (Preparation); (Preparation); THU (Therapeutic use); B10L (Biological study); PREP (Preparation); USES (Uses)
RM	Drug candidate; prepn. of nicotinamide derivs. and their use as therapeutic agents for treating stearoyl-CoA desaturase-mediated diseases
RM	361209-79-5 HCAPLUS 3-[(1-imidazol-1-yl)propyl]-6-[4-[(2,3,4,5- tetrafluorobenzoyl)-1-piperidinyl]-N]-(CA INDEX NAME)




RN 361209-79-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-(1H-imidazol-1-yl)propyl)- (CA INDEX NAME)



RN 361209-80-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 361209-81-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 361209-88-3 HCAPLUS
CN 3-Pyridinecarboxanide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)

[illegible]


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 361210-17-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 361450-94-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 361451-03-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[2-(3-chlorophenyl)ethyl]- (CA INDEX NAME)




RN 361451-43-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[2-(3-chlorophenyl)ethyl]- (CA INDEX NAME)




RN 361452-29-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-4-yl)ethyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361452-33-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 361452-34-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 361452-43-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 361452-60-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 361452-63-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361464-30-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 361464-42-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)



RN 361465-01-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 361465-07-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 361466-83-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361453-93-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 361454-25-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(1-methyl-3-phenylpropyl)- (CA INDEX NAME)



RN 361464-05-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 361464-25-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 361464-27-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361466-93-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 361466-96-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 361466-99-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 361467-19-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-butoxypropyl)- (CA INDEX NAME)




RN 361467-87-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361467-99-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-butoxypropyl)- (CA INDEX NAME)




RN 361526-44-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-phenylpropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 361526-48-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 361526-49-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 361526-54-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361991-32-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 503281-65-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503281-66-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503281-67-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503281-81-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-butyl- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361526-74-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 361538-99-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(1-methyl-3-phenylpropyl)- (CA INDEX NAME)



RN 361540-17-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 361980-14-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 361989-24-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503282-19-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503317-33-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503317-38-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 503317-39-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 503317-40-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503317-47-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 503318-61-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503318-65-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 503318-66-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 503318-74-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503324-98-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 503325-91-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503325-96-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)




RN 503325-97-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)




RN 503326-04-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503318-94-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503324-63-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 503324-68-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 503324-76-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 503324-96-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503326-24-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)




RN 503326-27-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)



RN 503326-86-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503327-14-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)




RN 503327-17-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 503421-63-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503421-73-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)



RN 503421-75-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)




RN 503421-77-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)




RN 503421-94-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 503453-44-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 503453-47-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)



RN 504417-35-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 504417-38-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 504417-46-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 503422-32-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)




RN 503422-36-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)



RN 503453-15-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503453-18-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 503453-26-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 504418-10-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 504425-73-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)



RN 504426-87-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 504428-07-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 504429-46-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852548-17-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-6-[4-(5-fluoro-2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852548-21-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclobutylethyl)-6-[4-(5-fluoro-2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-22-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclopropylpropyl)-6-[4-(5-fluoro-2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-24-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(5-fluoro-2-(trifluoromethyl)benzoyl)-1-piperazinyl]-N-(4-methylpentyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852548-65-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-67-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 852548-69-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-4-(trifluoromethyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-71-1 HCAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-5-fluoro-N-(3-methylbutyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-73-3 HCAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(3-methylbutyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852548-26-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3,3-dimethylbutyl)-6-[4-(5-fluoro-2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-28-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852548-39-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-1,2-dihydro-2-oxo-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-47-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 852548-58-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2-mercaptobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852548-81-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-(3-chlorophenyl)ethyl)-6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-83-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-oxo-4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)



RN 852548-85-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[2-oxo-4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-91-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-92-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)




RN 852548-94-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852549-03-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)




RN 852549-05-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-phenylpropyl)-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852549-11-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(1-methyl-3-phenylpropyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)




RN 852549-15-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852549-17-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 852549-77-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-[(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852549-89-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852549-91-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)




RN 852549-93-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852549-95-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852549-97-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852549-99-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-01-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)


RN 852550-03-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-05-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-07-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852550-09-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-11-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-14-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-17-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl)- (CA INDEX NAME)




RN 852550-19-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl)-N-(2-phenylethyl)- (CA INDEX NAME)




RN 852550-21-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl)-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 852550-23-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-6-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl)- (CA INDEX NAME)




RN 852550-25-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl)- (CA INDEX NAME)




RN 852550-38-0 HCAPLUS


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-46-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-(1-methylethoxy)propyl)- (CA INDEX NAME)




RN 852550-47-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852550-48-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-50-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-(1-methylethoxy)propyl)- (CA INDEX NAME)




RN 852550-51-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-(1-methylethoxy)propyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 852550-41-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(2-(ethylthio)ethyl)- (CA INDEX NAME)




RN 852550-42-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852550-43-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-44-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)




RN 852550-45-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-52-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-53-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)



RN 852550-54-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-55-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 852550-56-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-57-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)




RN 852550-58-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(2-ethylthio)ethyl)- (CA INDEX NAME)



RN 852550-59-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[1,3-dimethylbutyl]-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-60-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)




RN 852550-61-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-68-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 852550-69-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)



RN 852550-70-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)




RN 852550-71-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-methoxypropyl]-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-72-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-62-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-64-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852550-65-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)




RN 852550-66-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)




RN 852550-67-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-73-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-74-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-75-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-76-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-77-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 852550-78-8 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-79-9 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-80-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)



RN 852550-81-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 852550-82-4 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-83-5 HCAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-89-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)




RN 852550-90-4 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-91-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)




RN 852550-92-6 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-93-7 HCAPLUS
 CN 3-Pyridinecarboxamide, N-butyl-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-84-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)




RN 852550-85-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)



RN 852550-86-8 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-87-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)




RN 852550-88-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 852550-94-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)




RN 852550-95-9 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-96-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)



RN 852550-97-1 HCAPLUS
 CN 3-Pyridinecarboxamide, N-hexyl-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-98-2 HCAPLUS
 CN 3-Pyridinecarboxamide, N-hexyl-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-99-3 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-00-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)




RN 852551-01-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)



RN 852551-02-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-03-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)




RN 852551-04-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylethoxypropyl)-6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxypropyl)- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 852551-09-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-10-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-11-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-12-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-13-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)




RN 852551-14-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-05-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-06-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-07-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-08-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-15-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-16-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-17-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-19-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 852551-22-5 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)





RN 852551-23-6 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-24-7 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852551-25-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 852551-30-5 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 852551-31-6 HCAPLUS
 CN 3-Pyridinecarboxamide, N-hexyl-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-34-9 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 852551-35-0 HCAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-36-1 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-38-3 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-39-4 HCAPLUS
 CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-41-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-42-9 HCAPLUS
CN 3-Pyridinecarboxanide, N-(2-methylbutyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-43-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-44-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


121 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




```

RN      852551-45-2  HCAPLUS
CN      3-Pyridinecarboxamide, N-butyl-6-[4-(2-naphthalenylcarbonyl)-1-
        piperazinyl]- (CA INDEX NAME)


```




RN 852551-46-3 HCAPLUS
CN 3-Pyridinecarboxanide, N-(3-butoxypropyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-47-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-48-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-49-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-50-9 HCAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-51-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-52-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



II
825551-54-3P, N-(2-Cyclopropylethyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 825551-55-4P, N-(1-Methyl-2-phenylethyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 825551-56-3P, N-[3-(Methyl-2-phenylethyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 825551-57-4P, 6-[4-(Naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-(3-phenylbutyl)nicotinamide 825551-59-6P, 6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-(3-phenylbutyl)nicotinamide 825551-60-5P, N-[2-(3-Chlorophenylethyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 825551-61-4P, N-[2-(3-chlorophenylethyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide

121 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

82551-66-7P, N-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]-N-phenylnicotinicinamide 82551-69-0P, N-[1-Methyl-3-phenylpropyl]-N-(4-phenylbutyl)nicotinicinamide 82551-70-3P, N-[2-(3-Imidazol-4-yl)ethyl]-6-[4-[(Naphthalen-1-yl) carbonyl]piperazin-1-yl]nicotinicinamide 82551-73-4P, 6-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]-N-[(Tetrahydrofuran-2-yl)methyl]nicotinicinamide 82551-74-8P, N-[2-(3-Phenylpropyl)-4-yl]ethyl]-6-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]-N-[(Tetrahydrofuran-2-yl)methyl]nicotinicinamide 82551-72-6P, N-[3-(Imidazol-1-yl)propyl]-6-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]nicotinicinamide 82551-75-8P, N-[2-(3-Imidazol-4-yl)ethyl]-6-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]nicotinicinamide 82551-75-8P, 6-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]-N-phenethylnicotinicinamide 82551-76-9P, N-[2-(3-Phenylbutyl)-4-yl]ethyl]-6-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]nicotinicinamide 82551-77-0P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]nicotinicinamide 82551-78-1P, N-[2-(3-Phenylbutyl)-4-yl]ethyl]-6-[4-[(Naphthalen-1-yl) carbonyl]piperazin-1-yl]nicotinicinamide 82551-83-8P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-[(2-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-84-9P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-[(2-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-85-0P, N-(3-Phenylpropyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-86-1P, N-(4-Phenylbutyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-87-2P, N-(3-Phenylpropyl)-6-[4-[(3-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-88-3P, 6-[4-[(2-Bromobenzoyl) piperazin-1-yl]-N-(2-Methyl-3-phenylpropyl)nicotinicinamide 82551-89-4P, N-(3-Phenylbutyl)-6-[4-[(2-Methyl-3-phenylpropyl) piperazin-1-yl]-N-(5-Phenylpentyl)nicotinicinamide 82551-90-7P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-[(2-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-91-8P, N-(4-Phenylbutyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-92-9P, N-[2-(3-4,5-Dichlorobenzoyl) piperazin-1-yl]-N-(1-Methyl-3-phenylpropyl)nicotinicinamide 82551-93-1P, N-(3-Phenylbutyl)-6-[4-[(2-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-94-1P, N-Phenethyl-6-[4-[(2-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-95-2P, N-(3-Phenylbutyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-96-3P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-97-4P, N-(3,5-Dichlorobenzoyl) piperazin-1-yl]-N-(4-Phenylbutyl)nicotinicinamide 82551-98-5P, N-(1-Methyl-3-phenylpropyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82551-99-6P, N-(3-(3H-Imidazol-4-yl)ethyl)-6-[4-[(3-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-00-3P, N-(2-(3H-Imidazol-4-yl)ethyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-01-3P, N-(3-Imidazol-1-yl)propyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-02-5P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-[(3-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-04-6P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-[(3-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-05-7P, N-[2-(3H-Imidazol-4-yl)ethyl]-6-[4-[(2-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-06-8P, N-(2-(3-Chlorophenyl)ethyl)-6-[4-[(3-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-07-9P, N-(3-Phenylbutyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-08-0P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-[(3-Dichlorobenzoyl) piperazin-1-yl]nicotinicinamide 82552-09-1P, N-(3-Phenylbutyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-10-4P, 6-[4-[(2,4-Dichlorobenzoyl) piperazin-1-yl]-N-(4-Phenylbutyl)nicotinicinamide 82552-11-5P, 6-[4-[(2,5-Dichlorobenzoyl) piperazin-1-yl]-N-(4-Phenylbutyl)nicotinicinamide 82552-12-2P, N-(3-Imidazol-4-yl)ethyl)-6-[4-[(4-Trifluoromethylbenzoyl) piperazin-1-yl]nicotinicinamide 82552-63-7P, 6-[4-[(Naphthalen-2-yl) carbonyl]piperazin-1-yl]-N-phenethylnicotinicinamide 82552-64-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TH (Therapeutic use); BIOL (Biological study); PREP (Preparation); USE (Uses)
(drug candidate; prepn. of nicotinamide derivs. and their use as therapeutic agents for treating stearyl-CoA desaturase-mediated diseases)

RN 852551-54-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-6-[4-(3-


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-55-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-2-phenylethyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-56-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-2-phenylethyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-57-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)




RN 852551-59-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



RN 852551-65-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-66-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 852551-69-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-61-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 852551-64-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

PAGE 1-A




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852551-70-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 852551-71-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 852551-72-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A



RN 852551-73-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-74-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-75-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A




RN 852551-83-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(2-fluoro-4-methylbenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-84-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-85-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-phenylpropyl)-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-86-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-87-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-phenylpropyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852551-76-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)




RN 852551-77-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-78-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


PAGE 1-A




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-88-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(2-methyl-3-phenylpropyl)- (CA INDEX NAME)




RN 852551-89-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(5-phenylpentyl)- (CA INDEX NAME)



RN 852551-90-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-91-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-92-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(1-methyl-3-phenylpropyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-93-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-94-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852551-95-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(2-phenylethyl)methyl]-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-96-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(tetrahydro-2-furanyl)methyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-97-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852552-03-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(tetrahydro-2-furanyl)methyl]-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-04-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(tetrahydro-2-furanyl)methyl]-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-05-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(2-(1H-imidazol-5-yl)ethyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852552-06-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(2-(3-chlorophenyl)ethyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-07-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(2-(3-chlorophenyl)ethyl)-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-08-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(2-(3-chlorophenyl)ethyl)-6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-98-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-99-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852552-00-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-01-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-02-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852552-09-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(4-phenylbutyl)-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-10-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)



RN 852552-11-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)




RN 852552-12-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852552-63-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L21 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:29200 HCAPLUS
 DN 142:134463
 TI Preparation of 2-phenyl-N-(pyridin-3-yl)-N-methylisobutylamide derivatives
 as dual NK1/NK3 antagonists for treating schizophrenia
 IN Hoffmann, Torsten; Koblet, Andreas; Peters, Jens-Uwe; Schnider, Patrick;
 Sleight, Andrew; Stadler, Heinz
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT int. Appl., 374 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2005002577	A1	20050113	2004WO-EP0006929	20040625 <--
W: AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, US, US, VE, VC, VN, YU, ZA, ZM, ZW				
RM: BW, CH, GM, GE, LS, MM, ME, NA, SD, SI, SE, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU-2004253267	A1	20050113	2004AU-000253267	20040625 <--
CA-2530806	A1	20050113	2004CA-002530806	20040625 <--
EP-1643998	A1	20060412	2004EP-000740337	20040625 <--
EP-1643998	B1	20070829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR-2004012291	A	20060919	2004BR-00012291	20040625 <--
CN-1852712	A	20061025	2004CN-080025360	20040625 <--
AT-371451	T	20070915	2004AT-000740337	20040625 <--
ES-2291891	T3	20080301	2004ES-000740337	20040625 <--
US-20050090533	A1	20050428	2004US-000884707	20040702 <--
NO-200506007	A	20060119	2005NO-00006007	20051216 <--
IN-2006CN0020	A	20070608	2006IN-CN000020	20060103 <--
KR-74859	B1	20070801	2006KR-000700167	20060103 <--
MX-2006PA0192	A	20060411	2006MX-PA0000192	20060105 <--
PRAI 2003EP-00014513	A	20030703		
2004WO-EP0006929	W	20040625		
OS MARPAT 142:134463				
GI				

L21 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB The invention is directed to the use of compds. of formula I [wherein R1 = (un)substituted aryl; R2, R3 = independently H, halo, alkyl, alkoxy, OCHF2, OCH2F, OCF3, or CF3; R4, R5 = independently H, CHO, (CH2)0-3, etc.; o = 0-3; p = 0-2; or R4NR5 form an (un)substituted ring with -(CH2)3-5-, -(CH2)1,2,3-O-(CH2)2-, -CH2CH:CHCH2-, etc.;] and their pharmaceutically active acid addition salts as dual neurokinin NK1/NK3 antagonists useful in the treatment of schizophrenia. The invention discloses 421 preps. of title compds. For example, II was prepared, in 2 steps, by acylation of N-[6-chloro-4-(2-chlorophenyl)pyridin-3-yl]methylamine (preparation given) with 2-(3,5-dichlorophenyl)-2-methylpropanoyl chloride (preparation given) and amination with (L)-prolinol. II bound to NK1 and NK3 receptors with pKi value of 8.47 and 9.05, resp.

II 825639-95-OP, 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)piperazin-1-yl]pyridin-3-yl]-N-methylisobutylamide 825643-36-1P, (S)-2-[3,5-bis(trifluoromethyl)phenyl]-N-[6-[4-(cyclopropylcarbonyl)-2-hydroxymethylpiperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-N-methylisobutylamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-(pyridin-3-yl)-N-methylisobutylamide derivs. as dual NK1/NK3 antagonists for treating schizophrenia)


CN 825639-95-0 HCAPLUS
 Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)-1-piperazinyl]-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)



PN 825643-36-1 HCAPLUS
 Benzeneacetamide, N-[6-[(2S)-4-(cyclopropylcarbonyl)-2-(hydroxymethyl)-1-piperazinyl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


L21 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 RN 2002:775262 HCAPLUS
 DN 138:187738
 TI 2-[4-(p-acetamidophenylcarbonyl)piperazin-1-yl]-3-(N-arylthioureidocarbonyl)pyridines as antibacterial agents
 AU Patel, N. B.; Bhagat, P. R.
 CS Department of Chemistry, South Gujarat University, Surat, 395 007, India
 SO Indian Journal of Heterocyclic Chemistry (2002), 12(1), 83-84
 CODEN: IJCHEH; ISSN: 0971-1627
 PB Prof. R. S. Varma
 DT Journal
 LA English
 OS CASREACT 138:187738

The title compds. were prepared in 54-75% yields from 2-chloro-3-(arylthioureidocarbonyl)pyridines and 4-(p-acetamidophenylcarbonyl)piperazine. The antibacterial activity of the title compds. was tested against *Staphylococcus aureus* and *Escherichia coli*. Active to highly active activity was observed
 499131-82-7P 499131-83-8P 499131-84-9P
 499131-85-0P 499131-86-1P 499131-87-2P
 499131-88-3P 499131-89-4P 499131-90-7P
 499131-91-8P 499131-92-9P 499131-93-0P
 RJ: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antibacterial activity of [(acetamidophenylcarbonyl)piperazinyl](N-arylthioureidocarbonyl)pyridines)
 RN 499131-82-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[(phenylamino)thioxomethyl]- (CA INDEX NAME)




RN 499131-83-8 HCAPLUS
 CN Benzoic acid, 4-[[[2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-3-pyridinyl]carbonyl]amino]thioxomethyl]amino]- (CA INDEX NAME)




RN 499131-84-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[2-methoxyphenyl]amino]thioxomethyl]- (CA INDEX NAME)




L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 499131-89-4 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[2-nitrophenyl]amino]thioxomethyl]- (CA INDEX NAME)



RN 499131-90-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[3-nitrophenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-91-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[4-nitrophenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-92-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[3-chlorophenyl]amino]thioxomethyl]- (CA INDEX NAME)


L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 499131-85-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[4-methoxyphenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-86-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[2-methylphenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-87-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[3-methylphenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-88-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[4-methylphenyl]amino]thioxomethyl]- (CA INDEX NAME)



L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 499131-93-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 2-[4-[4-(acetylamino)benzoyl]-1-piperazinyl]-N-[[4-chlorophenyl]amino]thioxomethyl]- (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2002:314905 HCAPLUS
 DN 136:1325568
 TI Preparation of 2-phenyl-4-piperazinylpiperidine-1-carboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS disorders
 IN Alvaro, Giuseppe; Di Fabio, Romano; Maragni, Paolo; Tampieri, Marsia;
 Tranquillini, Maria Elvira
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2002032867	A1	20020425	2001WO-GB0004580	20011012 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, ES, FI, FR, GB, GR, GE, GM, GU, HK, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SI, SE, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GG, GW, ML, MR, NE, SN, TD, TG				
CA-2425876	A1	20020425	2001CA-002425876	20011012 <--
AU-2001095723	A	20020429	2001AU-00095723	20011012 <--
US-20030716	A1	20030716	2001EP-000976453	20011012 <--
EP-1326832	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR-2001014637	A	20030930	2001BR-00014637	20011012 <--
JP-2004511544	T	20040415	2002JP-000536051	20011012 <--
JP-3940359	B2	20070704		
AT-278669	T	20041015	2001AT-000976453	20011012 <--
PT-1326832	T	20050131	2001PT-000976453	20011012 <--
ES-2227287	T3	20050401	2001ES-000976453	20011012 <--
EP-1524266	A1	20050420	2004EP-000077714	20011012 <--
EP-1524266	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR				
NZ-525091	A	20050429	2001NZ-000525091	20011012 <--
AU-2001295723	B2	20050526	2001AU-000295723	20011012 <--
AT-355271	T	20060315	2004AT-000077714	20011012 <--
HU-2003001459	A2	20060928	2003HU-000001459	20011012 <--
HU-2003001459	A3	20071128		
EP-1752448	A1	20070214	2006EP-000122021	20011012 <--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, SI				
ES-2282794	T3	20071016	2004ES-000077714	20011012 <--
IN-2003MM00366	A	20050211	2003IN-MM0000366	20030403 <--
NO-2003001561	A	20030614	2003NO-000001561	20030407 <--
NO-324468	B1	20071022		
ZA-2003002801	A	20040421	2003ZA-000002801	20030410 <--
MX-2003PA03536	A	20030807	2003MX-PA0003536	20030421 <--
US-20040014770	A1	20040122	2003US-000398264	20030729 <--
US-1113092	B2	20061010		
HK-1058788	A1	20050527	2004HK-000100241	20040113 <--
US-20050137208	A1	20050623	2004US-000994605	20041122 <--
US-7060702	B2	20060613		
AU-2005204234	A1	20050915	2005AU-000204234	20050824 <--
US-20060142302	A1	20060629	2006US-000358631	20060221 <--
US-7294630	B2	20071113		
US-2008021041	A1	20080124	2007US-000865211	20071001 <--
PRAI 2000GB-000025354	A	20001017		
2001EP-000976453	A3	20011012		
2004EP-000077714	A3	20011012		
2001WO-GB0004580	W	20011012		
2003US-000398264	A1	20030729		
2004US-000994605	A1	20041122		
2006US-000358631	A1	20060221		


L21 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 414910-46-6 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-[(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)]

Absolute stereochemistry.



RN 414910-48-8 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-[(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 OS MARPAT 136:1325568
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = halo or alkyl; R1 = alkyl; R2 = H or alkyl; R3 = H or alkyl; R4 = CF3; R5 = H, alkyl, or COP6; R6 = (cycloalkyl or (di)alkylamino; m = 0-3; n = 1-3; and pharmaceutically acceptable salts and solvates thereof] were prepared as tachykinin antagonists. For example, reductive amination 2-(R)-[4-(fluoro-2-methylphenyl)-4-oxopiperidine-1-carboxylic acid [1-(R)-[3,5-bis(trifluoromethyl)phenyl]ethyl]methanamide (preparation given) with 1-acetyl-piperazine using sodium triacetoxycarboxide gave a mixture of diastereomers. 4(R)-II and 4-(S)-II were separated by flash chromatog. and the latter converted to its HCl salt. In a neurokinin 1 (NK1) receptor binding affinity assay, 4-(S)-II+HCl displace [3H]-substance P from recombinant human NK1 receptors expressed in Chinese Hamster Ovary cell membranes with pK_i of 9.36. In addition, oral administration of 4-(S)-II+HCl to gerbils inhibited foot tapping induced by an NK1 agonist with ED₅₀ of 0.05 mg/kg. I are useful for the treatment of CNS disorders, pain, sleep disorders, cognitive disorders, substance abuse, allergic disorders, emesis, gastrointestinal disorders, and depressive states (no data).

IT 414910-47-7P, 4-(S)-[4-(4-Cyclopropylpiperazin-1-yl)-2-(R)-[4-(fluoro-2-methylphenyl) piperidine-1-carboxylic acid N-[1-(R)-[3,5-bis-trifluoromethylphenyl]ethyl]-N-methylamide
 RL: PAC (Pharmacological activity); PCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-47-7 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-[(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)]

Absolute stereochemistry.



IT 414910-46-6P, 4-(R)-[4-(4-Cyclopropylpiperazin-1-yl)-2-(R)-[4-(fluoro-2-methylphenyl) piperidine-1-carboxylic acid N-[1-(R)-[3,5-bis-trifluoromethylphenyl]ethyl]-N-methylamide 414910-48-8P, 4-(S)-[4-(4-Cyclopropylpiperazin-1-yl)-2-(R)-[4-(fluoro-2-methylphenyl) piperidine-1-carboxylic acid N-[1-(R)-[3,5-bis-trifluoromethylphenyl]ethyl]-N-methylamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)


L21 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:265388 HCAPLUS
 DN 134:295742
 TI Preparation of a combinatorial library of pyridine carboxamides and sulfonamides for various pharmaceutical uses
 IN Chen, Yuesu; Lang, Hengyuan; Pei, Yanzhong
 PA Treps Biosciences, Inc., USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2001025203	A1	20010412	2000WO-US0021204	20000803 <--
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US-6677452	B1	20040113	1999US-000410142	19990930 <--
EP-1218343	A1	20020703	2000EP-000953018	20000803 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRAI 1999US-000410142	A	19990930		
2000WO-US0021204	W	20000803		
OS MARPAT 134:295742				
GI				

AB A combinatorial library of pyridine carboxamides and sulfonamides, such as I (R1, R2, R3, R4 = H, OH, NO2, CN, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, acyloxy, phenylalkyl, heterocyclylalkyl, etc.; X=NR7R8; R6 = H, alkyl, alkenyl, Ph, naphthyl, phenylalkyl, heterocyclylalkyl, heteroaryl, heterocyclyl, etc.; R7, R8 = H, alkyl, heterocyclyl, cycloalkyl, cycloalkenyl, phenylalkyl, heterocyclylalkyl, etc.; D, E = NH, heteroarylene, heterocyclylene, etc.; W = alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, heteroarylene, etc.; X = CO, SO2), were prepared via solid-phase synthesis for a variety of pharmaceutical uses. Thus, pyridine carboxamide II was prepared starting from a primary amine R7NH2 (R7 = alkyl, alkenyl, etc.), 6-chloronicotinic acid, piperazine, and benzoic acid with the use of Merrifield resin. The prepared pyridine carboxamides and sulfonamides were tested for melanocortin receptor binding, antibacterial activity, and penile erection augmentation.

IT 334002-42-5DP, N-substituted derivative
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of a combinatorial library of pyridine carboxamides and sulfonamides via Merrifield solid-phase synthesis for a variety of pharmaceutical uses)

RN 334002-42-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-(4-benzoyl-1-piperazinyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 11:34:44 ON 29 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 11:34:44 ON 29 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:34:44 ON 29 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr 146 tot
```

146 ANSWER 1 OF 1 USPATFULL ON 57N (Continued)


phenylencyclopropylcarboxylpiperazin-1-yl]nicotinanamide
852549-93-2P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(2-ethyl-4-chlorobenzoyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotinanamide 852549-94-0P
N-(3-Phenyl)pyridine-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852549-11-2P, 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-N-(2-ethyl-4-chlorobenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinanamide 852549-15-6P, N-(1,3-Dimethylbutyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852549-17-8P
N-(2-(4-Bromo-2-chlorophenyl)ethyl)piperazin-1-yl]-N-(2-ethyl-4-chlorobenzoyl)piperazin-1-yl]nicotinanamide 852549-77-0P, N-Pentyl-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852549-89-4P, N-(3-Ethoxypropyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852549-91-8P, N-(2-Ethyl-4-chlorobenzoyl)piperazin-1-yl]-N-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852549-93-0P, N-(1,3-Dimethylbutyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852549-95-2P, N-(3-Methylbutyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852549-97-4P, N-(3-Methoxypropyl)piperazin-1-yl]-N-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852549-99-6P, N-(3-Butoxypropyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-01-7D, N-(3-Dimethylaminopropyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-03-9P, N-(3-Isopropoxypropyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-05-1P, N-(1-Methylbutyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-07-3P, N-Butyl-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-09-5P, N-Hexyl-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-11-9P, N-(2-Methylbutyl)piperazin-1-yl]-N-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-14-2P, N-(4-Phenylbutyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-17-5P, N-(1-Methyl-3-phenylpropyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-19-7P, N-Penthenyl-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-21-1P, 4-(4-Phenylbutyl)piperazin-1-yl]-N-(2-tetrahydrofuran-2-yl)nicotinanamide 852550-23-3P, N-(2-(3H-Indazol-4-yl)ethyl)piperazin-1-yl]-N-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-25-5P, N-[3-(fmdazol-1-yl)propyl]-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-28-0P, 4-(4-(3-Dichlorobenzoyl)piperazin-1-yl)-N-(3-methoxypropyl)nicotinanamide 852550-41-5P, 6-(4-(2-4-Dichlorobenzoyl)piperazin-1-yl)-N-(2-ethyl-4-chlorobenzoyl)nicotinanamide 852550-42-6P, N-(3-Ethoxypropyl)piperazin-1-yl]-N-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852550-43-7P, N-(2-Ethyl-4-chlorobenzoyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852550-45-9P, N-(2-Ethyl-4-chlorobenzoyl)piperazin-1-yl]-N-(3-isopropoxypropyl)nicotinanamide 852550-45-9P, N-(3-Methylbutyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852550-46-0P
N-(4-(2,4-Dichlorobenzoyl)piperazin-1-yl)-N-(3-isopropoxypropyl)nicotinanamide 852550-47-1P, N-(3-Ethoxypropyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852550-48-3P, N-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852550-50-6P
6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-isopropoxypropyl)piperazin-1-yl]nicotinanamide 852550-51-7P, 6-[4-(2-4-Chlorobenzoyl)piperazin-1-yl]-N-(3-isopropoxypropyl)nicotinanamide 852550-52-8P, N-(3-Butoxypropyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinanamide 852550-53-0P, N-(2-Ethyl-4-chlorobenzoyl)piperazin-1-yl]-N-(2-ethyl-4-chlorobenzoyl)nicotinanamide 852550-54-0P, N-(3-Butoxypropyl)-6-[4-(2-phenylencyclopropylcarboxyl)piperazin-1-yl]nicotinanamide 852550-55-1P
N-(4-(3-Dichlorobenzoyl)piperazin-1-yl)-N-(3-methoxypropyl)nicotinanamide 852550-56-2P, 6-[4-(2-4-Dichlorobenzoyl)piperazin-1-yl]-N-(2-methylbutyl)nicotinanamide 852550-57-3P, 6-[4-(3-(3-Dichlorobenzoyl)piperazin-1-yl)-N-(2-methylbutyl)nicotinanamide 852550-58-4P, 6-[4-(2-4-Dimethylbenzoyl)piperazin-1-yl]-N-(2-ethyl-4-chlorobenzoyl)nicotinanamide 852550-59-6P

L46 ANSWER 1 OF 1 USPATFULL ON STN (Continued)
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-60-8P,
 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(2-methylbutyl)nicotinamide 852550-61-9P, N-(3-Dimethylaminopropyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-62-0P, N-Hexyl-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-64-2P, N-(3-Isopropoxypropyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-65-3P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-hexylnicotinamide 852550-66-4P, 6-[4-(2-Bromobenzoylethyl)piperazin-1-yl]-N-hexylnicotinamide 852550-67-5P, N-(3-Isopropoxypropyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-68-6P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotinamide 852550-69-7P, 6-[4-(2-Bromobenzoylethyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotinamide 852550-70-0P, 6-[4-(3,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-hexylnicotinamide 852550-71-1P, N-(3-Methoxypropyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-72-2P, 6-[4-(2,4-Dichlorobenzoylethyl)piperazin-1-yl]-N-hexylnicotinamide 852550-73-3P, N-(2-Ethylsulfanylethyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-74-4P, N-Pentyl-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-75-5P, N-(2-Methylbutyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-76-6P, N-(2-Ethylsulfanylethyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-77-7P, 6-[4-(2-Bromobenzoylethyl)piperazin-1-yl]-N-(2-methylbutyl)nicotinamide 852550-78-8P, N-(1,3-Dimethylbutyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-79-9P, N-(3-Methoxypropyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-80-2P, 6-[4-(2,4-Dimethylbenzoylethyl)piperazin-1-yl]-N-(1-methylbutyl)nicotinamide 852550-81-3P, 6-[4-(2,4-Dichlorobenzoylethyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotinamide 852550-82-4P, N-(1-Methylbutyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-83-5P, N-(3-Dimethylaminopropyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-84-6P, 6-[4-(2,4-Dichlorobenzoylethyl)piperazin-1-yl]-N-(1-methylbutyl)nicotinamide 852550-85-7P, 6-[4-(2,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-(1-methylbutyl)nicotinamide 852550-86-8P, N-(1-Methylbutyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-87-9P, 6-[4-(2,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-hexylnicotinamide 852550-88-0P, 6-[4-(2,4-Dimethylbenzoylethyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotinamide 852550-89-1P, 6-[4-(3,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-(1-methylbutyl)nicotinamide 852550-90-4P, N-(3-Butoxypropyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-91-5P, 6-[4-(2,4-Dimethylbenzoylethyl)piperazin-1-yl]-N-(3-isopropoxypropyl)nicotinamide 852550-92-6P, N-(1-Methylbutyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-93-7P, N-Butyl-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-94-8P, 6-[4-(2,4-Dimethylbenzoylethyl)piperazin-1-yl]-N-hexylnicotinamide 852550-95-9P, N-(3-Methoxypropyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-96-0P, 6-[4-(2,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-(2-methylbutyl)nicotinamide 852550-97-1P, N-Hexyl-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-98-2P, N-Hexyl-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-99-3P, N-(2-Methylbutyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-00-5P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(1-methylbutyl)nicotinamide 852551-01-0P, 6-[4-(2,4-Dimethylbenzoylethyl)piperazin-1-yl]-N-(2-methylbutyl)nicotinamide 852551-02-1P, N-(2-Methylbutyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-03-2P, 6-[4-(2-Bromobenzoylethyl)piperazin-1-yl]-N-(2-ethylsulfanylethyl)nicotinamide 852551-04-3P, 6-[4-(2-Bromo-5-methoxybenzoylethyl)piperazin-1-yl]-N-(3-isopropoxypropyl)nicotinamide 852551-05-4P, N-(1-Methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoylethyl)piperazin-1-yl]nicotinamide 852551-06-5P, N-(3-Methoxypropyl)-6-[4-(2,3,4,5-

L46 ANSWER 1 OF 1 USPATFULL ON STN (Continued)
 tetrafluorobenzoylethyl)piperazin-1-yl]nicotinamide 852551-07-6P, N-(3-Isopropoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoylethyl)piperazin-1-yl]nicotinamide 852551-08-7P, N-(2-Methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoylethyl)piperazin-1-yl]nicotinamide 852551-09-8P, N-Hexyl-6-[4-(2,3,4,5-tetrafluorobenzoylethyl)piperazin-1-yl]nicotinamide 852551-10-1P, N-(2-Ethylsulfanylethyl)-6-[4-(2,3,4,5-tetrafluorobenzoylethyl)piperazin-1-yl]nicotinamide 852551-11-2P, N-(3-Dimethylaminopropyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-12-3P, N-(3-Ethoxypropyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-13-4P, 6-[4-(3,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-(2-ethylsulfanylethyl)nicotinamide 852551-14-5P, N-(3-Methylbutyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-15-6P, N-Butyl-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-16-7P, N-(3-Isopropoxypropyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-17-8P, N-Pentyl-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-19-0P, N-Butyl-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-22-5P, N-(3-Butoxypropyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-23-6P, N-(3-Methoxypropyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-24-7P, N-(1-Methylbutyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-25-8P, 6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-pentylnicotinamide 852551-30-5P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-31-6P, N-Hexyl-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-34-8P, N-(1,3-Dimethylbutyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-35-0P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-36-1P, N-(1,3-Dimethylbutyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-38-3P, N-(2-Methylbutyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-39-4P, N-(2-Ethylsulfanylethyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-41-6P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-42-7P, N-(2-Methylbutyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-43-8P, N-(3-Methylbutyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-44-1P, N-(3-Butoxypropyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-45-2P, N-Butyl-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-46-3P, N-(3-Butoxypropyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-47-4P, N-(1-Methylbutyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-48-5P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-49-6P, N-Hexyl-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-50-7P, N-(3-Dimethylaminopropyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-51-0P, N-(2-Ethylsulfanylethyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide (drug candidate; prepn. of nicotinamide derivs. and their use as therapeutic agents for treating stearyl-CoA desaturase-mediated diseases)
 II 852551-52-1P, N-(3-Dimethylaminopropyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-54-3P, N-(2-Cyclopropylethyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-55-4P, N-(1-Methyl-2-phenylethyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-56-5P, N-(1-Methyl-2-phenylethyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-57-6P, 6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852551-59-8P, 6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 852551-61-2P, 6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 852551-64-5P, N-[2-(3-

L46 ANSWER 1 OF 1 USPATFULL ON STN (Continued)
 Chlorophenylethyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-65-6P, N-(1-Methyl-3-phenylpropyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-66-7P, 6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-phenethylnicotinamide 852551-69-0P, N-(1-Methyl-3-phenylpropyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-70-3P, N-[2-(3H-imidazol-4-yl)ethyl]-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-71-4P, 6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methyl]nicotinamide 852551-72-5P, 6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methyl]nicotinamide 852551-73-6P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-74-7P, N-[2-(3H-imidazol-4-yl)ethyl]-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-75-8P, 6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-phenethylnicotinamide 852551-76-9P, 6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852551-77-0P, N-[2-(3-Chlorophenylethyl)-6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-78-1P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-83-8P, N-[2-(3-Chlorophenylethyl)-6-[4-(2-fluoro-4-methylbenzoyl)piperazin-1-yl]nicotinamide 852551-84-9P, N-[2-(3-Chlorophenylethyl)-6-[4-(2,5-dichlorobenzoylethyl)piperazin-1-yl]nicotinamide 852551-85-0P, N-(3-Phenylpropyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-86-1P, N-(4-Phenylbutyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-87-2P, N-(3-Phenylpropyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-88-3P, 6-[4-(2-Bromobenzoylethyl)piperazin-1-yl]-N-(2-methyl-3-phenylpropyl)nicotinamide 852551-89-4P, 6-[4-(2-Bromo-5-methoxybenzoylethyl)piperazin-1-yl]-N-(5-phenylpentyl)nicotinamide 852551-90-7P, N-[2-(3-Chlorophenylethyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-91-8P, N-(4-Phenylbutyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-92-9P, 6-[4-(3,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-(3-methyl-3-phenylpropyl)nicotinamide 852551-93-0P, N-Phenethyl-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-94-1P, N-Phenethyl-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-95-2P, N-Phenethyl-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-96-3P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-97-4P, 6-[4-(3,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852551-98-5P, N-(1-Methyl-3-phenylpropyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-99-6P, N-[2-(3H-imidazol-4-yl)ethyl]-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-00-2P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-01-3P, N-[2-(3H-imidazol-4-yl)ethyl]-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-02-4P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-03-5P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-04-6P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-05-7P, N-[2-(3H-imidazol-4-yl)ethyl]-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-06-8P, N-[2-(3-Chlorophenylethyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-07-9P, N-[2-(3-Chlorophenylethyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-08-0P, N-[2-(3-Chlorophenylethyl)-6-[4-(3,5-dichlorobenzoylethyl)piperazin-1-yl]nicotinamide 852552-09-1P, N-(4-Phenylbutyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-10-4P, 6-[4-(2,4-Dichlorobenzoylethyl)piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852552-11-5P, 6-[4-(2,5-Dichlorobenzoylethyl)piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852552-12-6P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-63-7P, 6-[4-(naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-pentyl]nicotinamide (drug candidate; prepn. of nicotinamide derivs. and their use as therapeutic agents for treating stearyl-CoA desaturase-mediated diseases)
 II 852548-31-3P, N-(2-Cyclopropylethyl)-2-methoxy-6-[4-(2-

L46 ANSWER 1 OF 1 USPATFULL ON STN (Continued)
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide (drug candidate; prepn. of nicotinamide derivs. and their use as therapeutic agents for treating stearyl-CoA desaturase-mediated diseases)
 RN 852548-31-3 USPATFULL
 CN (trifluoromethylbenzoyl)-1-piperazinyl- (CA INDEX NAME)



=> d bib abs hitstr 147 tot

L47 ANSWER 1 OF 9 USPTFULL ON STN
 AN 2008:3860 USPTFULL
 TI Chemical Compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paola, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PI US-2008021041 A1 20080124
 AI 2007US-000865211 A1 20071001 (11)
 RLI Continuation of Ser. No. 2006US-000358631, filed on 21 Feb 2006,
 GRANTED, Pat. No. US-----7294630 Continuation of Ser. No.
 2004US-000994605, filed on 22 Nov 2004, GRANTED, Pat. No. US-----7060702
 Continuation of Ser. No. 2003US-000398264, filed on 29 Jul 2003,
 GRANTED, Pat. No. US-----7119092 A 371 of International Ser. No.
 2003WO-GB0004580, filed on 12 Oct 2001
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 PS APPLICATION
 LREP GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE
 DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
 CLAIM Number of Claims: 5
 ECL Exemplary Claims: 1-13
 DRWN No Drawings
 LN CNT 1659


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides a method for the treatment of emesis in a
 mammal being treated with an opioid analgesic

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414910-47-7P, 4-(S)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-
 fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS
 disorders)

RN 414910-47-7 USPTFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 414910-46-6P, 4-(R)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-
 fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P,
 4-(S)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-fluoro-2-
 methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS
 disorders)

RN 414910-46-6 USPTFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-

L47 ANSWER 2 OF 9 USPTFULL ON STN
 AN 2006:167791 USPTFULL
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paola, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PI US-20060142302 A1 20060629
 US-----7294630 B2 20071113
 AI 2006US-000358631 A1 20060221 (11)
 RLI Continuation of Ser. No. 2004US-000994605, filed on 22 Nov 2004, PENDING
 Continuation of Ser. No. 2003US-000398264, filed on 29 Jul 2003, PENDING
 A 371 of International Ser. No. 2003WO-GB0004580, filed on 12 Oct 2001
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 PS APPLICATION
 LREP GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE
 DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
 CLAIM Number of Claims: 4
 ECL Exemplary Claims: 1-13
 DRWN No Drawings
 LN CNT 1658
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compounds of formula (I): ##STR1##
 wherein


each R independently represents a halogen atom or a C.sub.1-4 alkyl group;
 R.sub.1 represents a C.sub.1-4 alkyl group;
 R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.3 represents hydrogen or C.sub.1-4 alkyl group;
 R.sub.4 represents a trifluoromethyl group;
 R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(OR).sub.2;
 R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl)
 or N(C.sub.1-4alkyl).sub.2; n is zero or an integer from 1 to 3; n is an
 integer from 1 to 3; or a pharmaceutically acceptable salt or solvate
 thereof; compositions containing the same, processes for their
 preparation and methods for their use in the treatment of conditions
 mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414910-47-7P, 4-(S)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-
 fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS
 disorders)

RN 414910-47-7 USPTFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



IT 414910-46-6P, 4-(R)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-
 fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P,
 4-(S)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-fluoro-2-


L47 ANSWER 1 OF 9 USPTFULL ON STN (Continued)
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPTFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L47 ANSWER 2 OF 9 USPTFULL ON STN (Continued)
 methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 (tachykinin antagonist; prepn. of piperazinylpiperidinecarboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS
 disorders)


RN 414910-46-6 USPTFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPTFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


L47 ANSWER 3 OF 9 USPATFULL ON STN
 AN 2005:158998 USPATFULL
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paolo, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PI US-20050137208 A1 20050623
 US-7060702 B2 20060613
 AI 2004US-000994605 A1 20041122 (10)
 RLI Continuation of Ser. No. 2003US-00099264, filed on 29 Jul 2003, PENDING
 A 371 of International Ser. No. 2001WO-GB0004580, filed on 12 Oct 2001
 PRAI 2000GB-000025354 20001017 <--
 DI Utility
 PS APPLICATION
 LREP DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE
 MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
 CLMN Number of Claims: 80
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2198
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compounds of formula (I): ##STR1##
 wherein
 each R independently represents a halogen atom or a C.sub.1-4 alkyl group;
 R.sub.1 represents a C.sub.1-4 alkyl group;
 R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.3 represents hydrogen or C.sub.1-4 alkyl group;
 R.sub.4 represents a trifluoromethyl group;
 R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(O)R.sub.6;
 R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl)
 or N(C.sub.1-4 alkyl).sub.2; n is zero or an integer from 1 to 3; n is an
 integer from 1 to 3; or a pharmaceutically acceptable salt or solvate
 thereof; compositions containing the same, processes for their
 preparation and methods for their use in the treatment of conditions
 mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 414910-47-7P, 4-(5)-(4-cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-47-7 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)
 Absolute stereochemistry.




IT 414910-46-6P, 4-(R)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-

L47 ANSWER 3 OF 9 USPATFULL ON STN (Continued)
 trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P,
 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 (tachykinin antagonist; prepn. of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-46-6 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)
 Absolute stereochemistry.




RN 414910-48-8 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



• HCL


L47 ANSWER 4 OF 9 USPATFULL ON STN
 AN 2005:105595 USPATFULL
 TI Dual NK1/NK3 receptor antagonists
 IN Hoffmann, Torsten, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF
 Koblet, Andreas, Binningen, SWITZERLAND
 Peters, Jens-Dew, Grenzsch-Wyhlen, GERMANY, FEDERAL REPUBLIC OF
 Schnider, Patrick, Oberwil, SWITZERLAND
 Sleight, Andrew, Riedisheim, FRANCE
 Stadler, Heinz, Rheinfelden, SWITZERLAND
 PI US-20050090523 A1 20050428
 AI 2004US-000884707 A1 20040702 (10)
 PRAI 2003EP-000014513 20030703 <--
 DI Utility
 PS APPLICATION
 LREP HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET,
 NUTLEY, NJ, 07110, US
 CLMN Number of Claims: 37
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 13501
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula ##STR1## wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 825639-95-0P, 2-[3,5-Bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)piperazin-1-yl]pyridin-3-yl]-N-methylisobutyramide 825643-16-1P, (S)-2-[3,5-Bis(trifluoromethyl)phenyl]-N-[6-[4-(cyclopropylcarbonyl)-2-(hydroxymethyl)piperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-N-methylisobutyramide
 (drug candidate; preparation of N-(pyridin-3-yl)-N-methylisobutyramide derivs. as dual NK1/NK3 antagonists for treating schizophrenia)
 RN 825639-95-0 USPATFULL
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)-1-piperazinyl]-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)



RN 825643-16-1 USPATFULL
 CN Benzeneacetamide, N-[6-[4-(2S)-4-(cyclopropylcarbonyl)-2-(hydroxymethyl)-1-piperazinyl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)
 Absolute stereochemistry.

L47 ANSWER 4 OF 9 USPATFULL ON STN (Continued)



L47 ANSWER 5 OF 9 USPTATFULL on STN
 AN 2004:19466 USPTATFULL
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paolo, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PI US-20040014770 A1 20040122
 US-----7119092 B2 20061010
 AI 2003US-000398264 A1 20030729 (10) <--
 2001WO-GB0004580 20011012 <--
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 FS APPLICATION
 LREP DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE
 MOORE DR., DO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
 CLMN Number of Claims: 13
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1778

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Formula (1) wherein R represents a halogen atom or a C.sub.1-4 alkyl group; R.sub.1 represents a C.sub.1-4 alkyl group; R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group; R.sub.3 represents hydrogen, or a C.sub.1-4 alkyl group; R.sub.4 represents a trifluoromethyl group; R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(0)R.sub.6; .sup.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl) or N(C(1-4alkyl).sub.2); n is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI 414910-47-7P, 4-(5)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-47-7 USPTATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



TI 414910-46-6P, 4-(R)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P, 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid


L47 ANSWER 5 OF 9 USPTATFULL on STN (Continued)
 phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-46-6 USPTATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPTATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L47 ANSWER 6 OF 9 USPTATFULL on STN
 AN 2004:9659 USPTATFULL
 TI Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
 IN Chen, Yuewu, San Diego, CA, United States
 Lang, Hengyuan, San Diego, CA, United States
 Pei, Xianhong, Aliso Viejo, CA, United States
 PA Lion Bioscience AG, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
 PI US-----6677452 B1 20040113
 AI 1999US-000410142 19990930 (9) <--
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Aulakh, Charanjit S.
 LREP Law Office of David Spolter
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 2602


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pyridine carboxamide or sulfonamide derivative compounds of the following formula: ##STR1## wherein R.sub.1 to R.sub.6 have the meanings provided herein. The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing pyridine carboxamide or sulfonamide derivative compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI 334002-42-5DP, N-substituted derivative (preparation of a combinatorial library of pyridine carboxamides and sulfonamides via Merrifield solid-phase synthesis for a variety of pharmaceutical uses)

RN 334002-42-5 USPTATFULL
 CN 3-Pyridinecarboxamide, 6-(4-benzoyl-1-piperazinyl)- (CA INDEX NAME)



L47 ANSWER 7 OF 9 USPAT2 on STN
 AN 2006:167791 USPAT2
 TI Piperazinyl piperidine tachykinin antagonists
 IN Alvaro, Giuseppe, Verona, ITALY
 PA SmithKline Beecham Corporation, Philadelphia, PA, UNITED STATES (U.S. corporation)
 PI US-----7294630 B2 20071113
 AI 2006US-000358631 20060221 (11)
 RLI Continuation of Ser. No. 2004US-000994605, filed on 22 Nov 2004, Pat. No. US-----7060702 Continuation of Ser. No. 2004US-000398264, Pat. No. US-----7119092 A 371 of International Ser. No. 2001WO-GB0004580, filed on 12 Oct 2001
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: O'Sullivan, Peter
 LREP Morgan, Lorie Ann
 CLMN Number of Claims: 3
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compounds of formula (I):

##STR1## wherein


each R independently represents a halogen atom or a C.sub.1-4 alkyl group; R.sub.1 represents a C.sub.1-4 alkyl group; R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group; R.sub.3 represents hydrogen or C.sub.1-4 alkyl group; R.sub.4 represents a trifluoromethyl group; R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(0)R.sub.6; R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl) or N(C(1-4alkyl).sub.2); n is zero or an integer from 1 to 3; n is an integer from 1 to 3; or a pharmaceutically acceptable salt or solvate thereof; compositions containing the same, processes for their preparation and methods for their use in the treatment of conditions mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI 414910-47-7P, 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-47-7 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



TI 414910-46-6P, 4-(R)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P, 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-


L47 ANSWER 7 OF 9 USPAT2 on STN (Continued)
 RN 414910-46-6 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


L47 ANSWER 8 OF 9 USPAT2 on STN
 AN 2005:15898 USPAT2
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paolo, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PA SmithKline Beecham Corporation, Philadelphia, PA, UNITED STATES (U.S. corporation)
 PI US-----7060702 B2 20060613
 AI 2004US-00094605 20041122 (10)
 RLI Continuation of Ser. No. 2000US-000398264, PENDING A 371 of International Ser. No. 2001WO-GB0004580, filed on 12 Oct 2001
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: O'Sullivan, Peter
 LREP Morgan, Lorie Ann
 CLMN Number of Claims: 79
 ECL Exemplary Claim: 1
 DWM No Drawings
 LN.CNT 2203
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compounds of formula (I):

##STR1# wherein
 R independently represents a halogen atom or a C.sub.1-4 alkyl group;
 R.sub.1 represents a C.sub.1-4 alkyl group;
 R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.3 represents hydrogen or C.sub.1-4 alkyl group;
 R.sub.4 represents a trifluoromethyl group;
 R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(O)R.sub.6;
 R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl) or N(C.sub.1-4alkyl).sub.2;
 m is zero or an integer from 1 to 3;
 n is an integer from 1 to 3; or a pharmaceutically acceptable salt or solvate thereof; compositions containing the same, processes for their preparation and methods for their use in the treatment of conditions mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 414910-47-7P, 4-(S)-[4-(Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-47-7 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




L47 ANSWER 8 OF 9 USPAT2 on STN (Continued)

IT 414910-46-6P, 4-(R)-[4-(Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P, 4-(S)-[4-(Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)


RN 414910-46-6 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


L47 ANSWER 9 OF 9 USPAT2 on STN
 AN 2004:19466 USPAT2
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Maragni, Paolo, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 PA SmithKline Beecham Corporation, Philadelphia, PA, UNITED STATES (U.S. corporation)
 PI US-----7119092 B2 20061010
 WO-2002032867 20020425 <--
 AI 2001US-000398264 20011012 (10) <--
 2001WO-GB0004580 20011012 <--
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Raymond, Richard L.
 LREP Morgan, Lorie Ann
 CLMN Number of Claims: 41
 ECL Exemplary Claim: 1
 DWM 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 1749
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

##STR1# wherein
 R represents a halogen atom or a C.sub.1-4 alkyl group;
 R.sub.1 represents a C.sub.1-4 alkyl group;
 R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.3 represents hydrogen, or a C.sub.1-4 alkyl group;
 R.sub.4 represents a trifluoromethyl group;
 R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(O)R.sub.6;
 R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl) or N(C.sub.1-4alkyl).sub.2;
 m is zero or an integer from 1 to 3;
 n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 414910-47-7P, 4-(S)-[4-(Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-47-7 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(4-(cyclopropylcarbonyl)-1-piperazinyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 414910-46-6P, 4-(R)-[4-(Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P, 4-(S)-[4-(Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid

L47 ANSWER 9 OF 9 USPAT2 on STN (Continued)
phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-46-6 USPAT2

CN 1-piperidinecarboxamide, N-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-4-[[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-48-8 USPAT2

CN 1-piperidinecarboxamide, N-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-4-[[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

=> d his

(FILE 'HOME' ENTERED AT 10:50:55 ON 29 APR 2008)

FILE 'HCAPLUS' ENTERED AT 10:51:08 ON 29 APR 2008

L1 1 US20060293308/PN

FILE 'REGISTRY' ENTERED AT 10:51:20 ON 29 APR 2008

FILE 'HCAPLUS' ENTERED AT 10:51:22 ON 29 APR 2008

L2 TRA L1 1- RN : 56 TERMS

FILE 'REGISTRY' ENTERED AT 10:51:23 ON 29 APR 2008

L3 56 SEA L2

L4 43 L3 AND NC2NC2/ES AND NC5/ES

L5 43 L4 AND 46.156.30/RID

FILE 'REGISTRY' ENTERED AT 10:52:15 ON 29 APR 2008

L6 STR

L7 0 L6

L8 161791 NC5/ES AND NC2NC2/ES

L9 50 L6 SAM SUB=L8

L10 STR L6

L11 21 L10 SAM SUB=L8

L12 2038 L10 FULL SUB=L8

SAV TEM J857F1/A L12

L13 1 NAPHTHALENE/CN

L14 1854 (46.150.18 OR 591.49.57)/RID AND L12

L15 35 L14 AND L3

L16 1819 L14 NOT L15

FILE 'HCAPLUS' ENTERED AT 11:00:00 ON 29 APR 2008

L17 17 L16

L18 2 L15

L19 5 L17 AND (PD<=20030729 OR AD<=20030729 OR PRD<=20030729)

L20 3 L17 AND PD<=20020729

L21 5 L19-20

SEL HIT RN

FILE 'REGISTRY' ENTERED AT 11:04:13 ON 29 APR 2008

L22 303 E1-303

FILE 'HCAOLD' ENTERED AT 11:12:56 ON 29 APR 2008

L23 0 L16

L24 0 L15

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:13:11 ON 29 APR 2008

L25 0 L15

L26 11 L16

L27 10 L26 AND (PD<=20030729 OR AD<=20030729 OR PRD<=20030729)

L28 1 L26 AND PD<=20020729

L29 10 L27-28

L30 0 L26 AND XENON/CS,PA

E ABREO M/AU

L31 21 E4-5

E HARVEY D/AU

L32 5 E3

E HARVEY DAN/AU

L33 19 E3,E5-11

L34 17 E3,E5-9

E KONDRATENKO M/AU

L35 3 E6-7

E LI W/AU

E LI WEN/AU

L36 182 E3

E LI WENBAO/AU

L37 7 E3

E LI WEN B/AU

E KAMBOJ R/AU

L38	56 E4-5
	E WINTHER M/AU
L39	20 E6-7
	E GSCHWEND H/AU
L40	41 E3,E5-7
	E CHAKKA N/AU
L41	8 E4-5
	E LIU S/AU
L42	1 E3
	E LIU SHI/AU
	E LIU SHIFENG/AU
L43	14 E3
	E SVIRIDOV S/AU
L44	22 E4-7
	E SUN S/AU
	E SUN SHAO/AU
	E SUN SHAOYI/AU
L45	11 E3
L46	1 L29 AND L26 AND L31-45
L47	9 L29 NOT L46

=>